ES2330774T3 - Uso de 1-(4-(5-cianoindol-3-il)butil)-4-(2-carbamoil-benzofuran-5-il)-piperazina y sus sales farmacologicamente aceptables. - Google Patents

Uso de 1-(4-(5-cianoindol-3-il)butil)-4-(2-carbamoil-benzofuran-5-il)-piperazina y sus sales farmacologicamente aceptables. Download PDF

Info

Publication number
ES2330774T3
ES2330774T3 ES06017231T ES06017231T ES2330774T3 ES 2330774 T3 ES2330774 T3 ES 2330774T3 ES 06017231 T ES06017231 T ES 06017231T ES 06017231 T ES06017231 T ES 06017231T ES 2330774 T3 ES2330774 T3 ES 2330774T3
Authority
ES
Spain
Prior art keywords
benzofuran
piperazine
carbamoyl
butyl
cyanoindole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06017231T
Other languages
English (en)
Spanish (es)
Inventor
Gerd Bartoszyk
Christoph Seyfried
Christoph Van Amsterdam
Henning Boettcher
Ewen Sedman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2330774(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2330774T3 publication Critical patent/ES2330774T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES06017231T 1999-05-27 2000-05-16 Uso de 1-(4-(5-cianoindol-3-il)butil)-4-(2-carbamoil-benzofuran-5-il)-piperazina y sus sales farmacologicamente aceptables. Expired - Lifetime ES2330774T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99109295 1999-05-27
EP99109295 1999-05-27

Publications (1)

Publication Number Publication Date
ES2330774T3 true ES2330774T3 (es) 2009-12-15

Family

ID=8238153

Family Applications (3)

Application Number Title Priority Date Filing Date
ES06017231T Expired - Lifetime ES2330774T3 (es) 1999-05-27 2000-05-16 Uso de 1-(4-(5-cianoindol-3-il)butil)-4-(2-carbamoil-benzofuran-5-il)-piperazina y sus sales farmacologicamente aceptables.
ES04001441T Expired - Lifetime ES2271707T3 (es) 1999-05-27 2000-05-16 Uso de 1-(4-(5-cianoindol-3-il)butil)-4-(2-carbamoil-benzofuran-5-il)-piperazina y de sus sales fisiologicamente aceptables.
ES00935031T Expired - Lifetime ES2219342T3 (es) 1999-05-27 2000-05-16 Nuevo uso de 1-(5-cianoindol-3-il)butil)-4-(2-carbamoilbenzofuran-5-il)-piperazina y sus sales fisiologicamente aceptables para el tratamiento de trastornos bipolares y mania.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES04001441T Expired - Lifetime ES2271707T3 (es) 1999-05-27 2000-05-16 Uso de 1-(4-(5-cianoindol-3-il)butil)-4-(2-carbamoil-benzofuran-5-il)-piperazina y de sus sales fisiologicamente aceptables.
ES00935031T Expired - Lifetime ES2219342T3 (es) 1999-05-27 2000-05-16 Nuevo uso de 1-(5-cianoindol-3-il)butil)-4-(2-carbamoilbenzofuran-5-il)-piperazina y sus sales fisiologicamente aceptables para el tratamiento de trastornos bipolares y mania.

Country Status (31)

Country Link
US (4) US6900212B1 (enExample)
EP (3) EP1410800B1 (enExample)
JP (2) JP4884588B2 (enExample)
KR (1) KR100683367B1 (enExample)
CN (3) CN1198618C (enExample)
AR (1) AR024112A1 (enExample)
AT (3) ATE263564T1 (enExample)
AU (1) AU771778B2 (enExample)
BR (1) BR0010948A (enExample)
CA (3) CA2615271C (enExample)
CY (2) CY1105750T1 (enExample)
CZ (1) CZ295623B6 (enExample)
DE (3) DE60030338T2 (enExample)
DK (3) DK1736158T3 (enExample)
ES (3) ES2330774T3 (enExample)
HK (1) HK1048444B (enExample)
HU (1) HU229059B1 (enExample)
IL (2) IL146707A0 (enExample)
MX (1) MXPA01012172A (enExample)
MY (1) MY135627A (enExample)
NO (2) NO322120B1 (enExample)
PL (3) PL199650B1 (enExample)
PT (3) PT1736158E (enExample)
RU (1) RU2237477C2 (enExample)
SI (2) SI1410800T1 (enExample)
SK (1) SK287851B6 (enExample)
TR (1) TR200103361T2 (enExample)
TW (1) TW518218B (enExample)
UA (1) UA74337C2 (enExample)
WO (1) WO2000072832A2 (enExample)
ZA (1) ZA200110485B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
UA76130C2 (en) * 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
DE10112151A1 (de) * 2001-03-14 2002-09-19 Merck Patent Gmbh Substituierte Benzofuran-2-carbonsäureamide
UA76758C2 (uk) 2001-06-19 2006-09-15 Мерк Патент Гмбх Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
DE10305739A1 (de) * 2003-02-11 2004-08-19 Merck Patent Gmbh Benzofuranderivate
US20040192730A1 (en) * 2003-03-13 2004-09-30 Dynogen Pharmaceuticals, Inc. Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction
WO2005094896A2 (en) * 2004-03-26 2005-10-13 Baylor University Targeted serotonin reuptake inhibitors
CA2651663A1 (en) 2006-05-30 2007-12-06 Astrazeneca Ab Chemical compounds
TW200932235A (en) 2007-12-20 2009-08-01 Astrazeneca Ab Carbamoyl compounds as DGAT1 inhibitors
RU2011152517A (ru) 2009-06-19 2013-07-27 Астразенека Аб Пиразинкарбоксамиды в качестве ингибиторов dgat1
AU2010316106B2 (en) 2009-11-06 2015-10-22 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
CA2779442A1 (en) 2009-11-06 2011-05-12 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
WO2012131706A1 (en) 2011-03-20 2012-10-04 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for its preparation
CN102949364A (zh) * 2011-08-30 2013-03-06 天津药物研究院 一种含有效成分盐酸维拉佐酮的缓释片
US9382233B2 (en) 2012-06-13 2016-07-05 Apotex Inc. Forms of vilazodone and processes for the preparation thereof
CN102860993A (zh) * 2012-10-16 2013-01-09 北京诚创思达医药科技有限公司 一种盐酸维拉唑酮快速释放片剂及其制备方法
WO2014064715A2 (en) 2012-10-22 2014-05-01 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for preparing thereof
CN102977083A (zh) * 2012-12-17 2013-03-20 南京海纳医药科技有限公司 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的新晶型xⅶ及其制备方法
RS59687B1 (sr) 2013-01-22 2020-01-31 Vistagen Therapeutics Inc Oblici doziranja i terapeutske primene l-4-hlorkinurenina
EP2824104A1 (en) 2013-07-12 2015-01-14 Sandoz AG Process for the preparation of form III of Vilazodone hydrochloride
CN107949379A (zh) * 2015-05-22 2018-04-20 维斯塔津治疗公司 L‑4‑氯代犬尿氨酸的治疗用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672052B1 (fr) * 1991-01-28 1995-05-24 Esteve Labor Dr Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments.
SE9201239D0 (sv) * 1992-04-21 1992-04-21 Kabi Pharmacia Ab Agents for treating substance abuse disorders
DE4333254A1 (de) * 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
DE19514567A1 (de) * 1995-04-20 1996-10-24 Merck Patent Gmbh Benzofurane
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5914394A (en) * 1997-03-27 1999-06-22 Millenium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
US6470933B1 (en) * 1998-03-09 2002-10-29 Pirelli Pneumatici S.P.A. Tire containing at least part of an electrical current generator intended for the supply of sensors and/or other electrical devices present within the tire, and method for manufacture the said tire
FR2781671A1 (fr) * 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
EP1612564A3 (en) * 2001-09-11 2009-12-09 JTEKT Corporation Magnetic pulser ring
FR2844591B1 (fr) * 2002-09-13 2005-04-15 Arvinmeritor Light Vehicle Sys Dispositif de determination du deplacement d'un arbre

Also Published As

Publication number Publication date
NO324230B1 (no) 2007-09-10
PT1736158E (pt) 2009-11-11
ZA200110485B (en) 2003-06-30
CA2615271A1 (en) 2000-12-07
CA2694866A1 (en) 2000-12-07
UA74337C2 (uk) 2005-12-15
WO2000072832A2 (en) 2000-12-07
HUP0201275A3 (en) 2004-04-28
HU229059B1 (en) 2013-07-29
AR024112A1 (es) 2002-09-04
EP1410800B1 (en) 2006-08-23
NO20015746D0 (no) 2001-11-26
SI1410800T1 (sl) 2007-02-28
CZ20014226A3 (cs) 2002-03-13
WO2000072832A3 (en) 2001-12-20
SK16462001A3 (sk) 2002-02-05
BR0010948A (pt) 2002-04-23
NO322120B1 (no) 2006-08-14
RU2237477C2 (ru) 2004-10-10
ATE438399T1 (de) 2009-08-15
EP1185272B1 (en) 2004-04-07
PL352373A1 (en) 2003-08-25
MY135627A (en) 2008-05-30
JP4884588B2 (ja) 2012-02-29
KR100683367B1 (ko) 2007-02-15
EP1410800A1 (en) 2004-04-21
US7642261B2 (en) 2010-01-05
CA2372668C (en) 2009-11-03
ATE337008T1 (de) 2006-09-15
DK1736158T3 (da) 2009-11-02
PL199516B1 (pl) 2008-09-30
SI1185272T1 (en) 2004-12-31
HK1048444A1 (en) 2003-04-04
CY1109472T1 (el) 2012-05-23
PL199650B1 (pl) 2008-10-31
CN1198618C (zh) 2005-04-27
EP1736158A3 (en) 2007-01-03
ES2271707T3 (es) 2007-04-16
IL146707A (en) 2007-06-03
CZ295623B6 (cs) 2005-09-14
US20080119484A1 (en) 2008-05-22
EP1736158B1 (en) 2009-08-05
ATE263564T1 (de) 2004-04-15
PL200490B1 (pl) 2009-01-30
TR200103361T2 (tr) 2002-05-21
EP1185272A2 (en) 2002-03-13
ES2219342T3 (es) 2004-12-01
TW518218B (en) 2003-01-21
JP2003500441A (ja) 2003-01-07
CN1361692A (zh) 2002-07-31
CY1105750T1 (el) 2010-12-22
AU771778B2 (en) 2004-04-01
MXPA01012172A (es) 2002-07-22
DE60009697T2 (de) 2005-04-14
PT1185272E (pt) 2004-08-31
HUP0201275A2 (en) 2002-08-28
CN101869565A (zh) 2010-10-27
DE60042710D1 (de) 2009-09-17
JP2011148799A (ja) 2011-08-04
NO20061562L (no) 2001-11-26
NO20015746L (no) 2001-11-26
US20100063062A1 (en) 2010-03-11
EP1736158A2 (en) 2006-12-27
US20050113386A1 (en) 2005-05-26
US6900212B1 (en) 2005-05-31
DE60030338T2 (de) 2007-08-16
HK1048444B (zh) 2005-12-09
DK1410800T3 (da) 2006-12-27
DE60009697D1 (de) 2004-05-13
CA2372668A1 (en) 2000-12-07
AU5066300A (en) 2000-12-18
US7371756B2 (en) 2008-05-13
IL146707A0 (en) 2002-07-25
KR20020008847A (ko) 2002-01-31
PT1410800E (pt) 2007-01-31
CN1679577A (zh) 2005-10-12
SK287851B6 (sk) 2012-01-04
DE60030338D1 (de) 2006-10-05
CA2615271C (en) 2011-02-15
DK1185272T3 (da) 2004-08-09

Similar Documents

Publication Publication Date Title
ES2330774T3 (es) Uso de 1-(4-(5-cianoindol-3-il)butil)-4-(2-carbamoil-benzofuran-5-il)-piperazina y sus sales farmacologicamente aceptables.
US8680105B2 (en) Method of treating down's syndrome
RU2221563C2 (ru) Фармацевтическая композиция для лечения болезни паркинсона и синдромов паркинсона, способ ее получения, способ лечения болезни паркинсона и синдромов паркинсона
TWI226829B (en) Pharmaceutical compositions for treatment of partial responders or refractory depression
US20060258640A1 (en) Use of Flibanserin in the treatment of chronic pain
JP2020164538A (ja) 関節病態の治療
JP2018501217A (ja) 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン
US11865119B2 (en) Methods of treating agitation and other dementia-associated behavioral symptoms
JPS60258117A (ja) ヒドロキシインドール誘導体を含有する血圧降下剤
JPH0320222A (ja) 脳内虚血症治療剤
ES2326078T3 (es) Medicamento destinado al sindrome de la disfuncion de integracion.
CA2339628C (en) Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of nk-1 receptor antagonists for the treatment of chronic fatigue syndrome
US6534507B1 (en) Methods for treating psychological disorders using bioactive metabolites of gepirone
JPH0820531A (ja) 緑内障治療剤及び眼圧降下剤
CN110075304A (zh) 一种治疗骨关节炎的药物组合物及其用途
KR20010021796A (ko) 선택성 세로토닌 재흡수 억제제 (ｓｓｒｉ)를 사용하는심장 질환의 치료 및 예방법
ES2263009T3 (es) Citalopram para el tratamiento de la presion sanguinea elevada.
JP2015124205A (ja) 無定形ブリモニジン酒石酸塩及びその製造方法
EA015503B1 (ru) Применение 4-циклопропилметокси-n-(3,5-дихлор-1-оксидопиридин-4-ил)-5-(метокси)пиридин-2-карбоксамида для лечения черепно-мозговых травм
ES2275913T3 (es) Derivados de piridin-2.il metilamina para el tratamiento de la dependencia de los opioides.
RU2322438C2 (ru) Азаспиросоединения для лечения болей
ES2319991T3 (es) Uso de 2-ciano-10-(2-metil-3-(metilamino)-propil)fenotiazina o su sal farmaceuticamente aceptable como un medicamento.
US20030220346A1 (en) Use of bioactive metabolites of gepirone for the treatment of psychological disorders
KR100413717B1 (ko) 레보부피바카인및임산부의마취제로서그것의용도
WO2021019479A2 (en) New formulations of amisulpride